@revmed.com
At Revolution Medicines our mission is to revolutionize treatment for patients with RAS-addicted cancers through targeted medicines.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
SVG
About
Description
Revolution Medicines is a clinical-stage precision oncology company dedicated to developing innovative targeted therapies. With a specific focus on RAS and associated signaling pathways, our goal is to inhibit elusive frontier targets within notorious growth and survival pathways. We leverage our deep understanding of genetic drivers and adaptive resistance mechanisms in cancer to build a portfolio of compounds that inhibit critical signaling nodes.
Our approach involves accessing unconventional sites on challenging targets using sophisticated structure-based drug discovery capabilities. Our most advanced and promising product candidate is RMC-4630, an exceptional drug candidate that selectively inhibits SHP2, a central node in the RAS signaling pathway. Through a multi-cohort Phase 1/2 clinical program conducted in collaboration with Sanofi, we are evaluating RMC-4630 for various tumor types with specific oncogenic mutations.
Additionally, we are developing a range of mutant-selective RAS inhibitors and inhibitors of other frontier oncology targets within the RAS and mTOR pathways. Our comprehensive strategy includes exploring mechanism-based dosing paradigms and in-pathway combinations to optimize cancer treatment. With our exceptional team and cutting-edge labs located in the heart of the Bay Area, we are at the forefront of translating frontier oncology targets to outsmart cancer.
Contact us today to learn more about our innovative solutions
Company Type
Public Company
Company Size
51-200
Year Founded
2014
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories